Hepatitis C Virus: Virology and Experimental Systems

Clinics in Liver Disease

Volumn 10, Issue 4, 2006, Pages 773-791

  Liu, Chen ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; HEPATITIS C VACCINE; PROTEINASE INHIBITOR; RIBAVIRIN;

CELL FUNCTION; DISEASE COURSE; EXPERIMENT; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; LIVER CELL; MICROENVIRONMENT; NONHUMAN; PATHOGENESIS; REPLICON; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; VIROLOGY; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS EXPRESSION;

ANIMALS; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; MICE; VIRUS REPLICATION;

EID: 33845314345     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.08.018     Document Type: Review

References (147)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
2. Liang T.J., Rehermann B., Seeff L.B., et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 (2000) 296-305
3. Cerny A., and Chisari F.V. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30 (1999) 595-601
4. Davis G.L. Combination treatment with interferon and ribavirin for chronic hepatitis C. Clin Liver Dis 3 (1999) 811-826
5. Choo Q.L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
6. Poynard T., Yuen M.F., Ratziu V., et al. Viral hepatitis C. Lancet 362 (2003) 2095-2100
7. Ji H., Fraser C.S., Yu Y., et al. Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. Proc Natl Acad Sci U S A 101 (2004) 16990-16995
8. Lohmann V., Koch J.O., and Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J Hepatol 24 2 Suppl (1996) 11-19
9. Penin F., Dubuisson J., Rey F.A., et al. Structural biology of hepatitis C virus. Hepatology 39 (2004) 5-19
10. Griffin S., Clarke D., McCormick C., et al. Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. J Virol 79 (2005) 15525-15536
11. Kato N., Yoshida H., Kioko Ono-Nita S., et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 32 (2000) 405-412
12. Ray R.B., Meyer K., and Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 226 (1996) 176-182
13. Zhu N., Khoshnan A., Schneider R., et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 72 (1998) 3691-3697
14. Hosui A., Ohkawa K., Ishida H., et al. Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli. J Biol Chem 278 (2003) 28562-28571
15. Miller K., McArdle S., Gale Jr. M.J., et al. Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res 24 (2004) 391-402
16. Shimotohno K., Watashi K., Tsuchihara K., et al. Hepatitis C virus and its roles in cell proliferation. J Gastroenterol 37 Suppl 13 (2002) 50-54
17. Kamegaya Y., Hiasa Y., Zukerberg L., et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 41 (2005) 660-667
18. Moriya K., Yotsuyanagi H., Shintani Y., et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 Pt 7 (1997) 1527-1531
19. Abrignani S., and Rosa D. Perspectives for a hepatitis C virus vaccine. Clin Diagn Virol 10 (1998) 181-185
20. Qiao M., Murata K., Davis A.R., et al. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 37 (2003) 52-59
21. Baumert T.F., Ito S., Wong D.T., et al. Hepatitis C virus structural proteins assemble into virus like particles in insect cells. J Virol 72 (1998) 3827-3836
22. Lechmann M., Murata K., Satoi J., et al. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34 (2001) 417-423
23. Taylor D.R., Shi S.T., Romano P.R., et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
24. Griffin S.D., Harvey R., Clarke D.S., et al. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 85 Pt 2 (2004) 451-461
25. Pavlovic D., Neville D.C., Argaud O., et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A 100 (2003) 6104-6108
26. Sakai A., Claire M.S., Faulk K., et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A 100 (2003) 11646-11651
27. Franck N., Le Seyec J., Guguen-Guillouzo C., et al. Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome. J Virol 79 (2005) 2700-2708
28. Prikhod'ko E.A., Prikhod'ko G.G., Siegel R.M., et al. The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology 329 (2004) 53-67
29. Breiman A., Grandvaux N., Lin R., et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. J Virol 79 (2005) 3969-3978
30. Loo Y.M., Owen D.M., Li K., et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A 103 (2006) 6001-6006
31. Tellinghuisen T.L., Marcotrigiano J., Gorbalenya A.E., et al. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 279 (2004) 48576-48587
32. Brass V., Bieck E., Montserret R., et al. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 277 (2002) 8130-8139
33. Moradpour D., Brass V., and Penin F. Function follows form: the structure of the N-terminal domain of HCV NS5A. Hepatology 42 (2005) 732-735
34. Tanji Y., Kaneko T., Satoh S., et al. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol 69 (1995) 3980-3986
35. Reed K.E., Xu J., and Rice C.M. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J Virol 71 (1997) 7187-7197
36. Ide Y., Tanimoto A., Sasaguri Y., et al. Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit. Gene 201 (1997) 151-158
37. Appel N., Pietschmann T., and Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 79 (2005) 3187-3194
38. Huang Y., Chen X.C., Konduri M., et al. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. Hepatology 43 (2006) 81-90
39. Macdonald A., and Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85 Pt 9 (2004) 2485-2502
40. Lesburg C.A., Cable M.B., Ferrari E., et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6 (1999) 937-943
41. Biswal B.K., Cherney M.M., Wang M., et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J Biol Chem 280 (2005) 18202-18210
42. Domitrovich A.M., Diebel K.W., Ali N., et al. Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication. Virology 335 (2005) 72-86
43. Luo G., Hamatake R.K., Mathis D.M., et al. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J Virol 74 (2000) 851-863
44. Ishii N., Watashi K., Hishiki T., et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80 (2006) 4510-4520
45. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
46. Flint M., and McKeating J.A. The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 10 (2000) 101-117
47. Meola A., Sbardellati A., Bruni Ercole B., et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 74 (2000) 5933-5938
48. Masciopinto F., Freer G., Burgio V.L., et al. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 304 (2002) 187-196
49. Cormier E.G., Tsamis F., Kajumo F., et al. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 101 (2004) 7270-7274
50. Flint M., Thomas J.M., Maidens C.M., et al. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 73 (1999) 6782-6790
51. Germi R., Crance J.M., Garin D., et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68 (2002) 206-215
52. Bartosch B., Vitelli A., Granier C., et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278 (2003) 41624-41630
53. Kronenberger B., Ruster B., Elez R., et al. Interferon alfa down-regulates CD81 in patients with chronic hepatitis C. Hepatology 33 (2001) 1518-1526
54. Levy S., Todd S.C., and Maecker H.T. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16 (1998) 89-109
55. Crotta S., Stilla A., Wack A., et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195 (2002) 35-41
56. Ni J., Hembrador E., Di Bisceglie A.M., et al. Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol 170 (2003) 3429-3439
57. Rosa D., Saletti G., De Gregorio E., et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 102 (2005) 18544-18549
58. Triyatni M., Saunier B., Maruvada P., et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 76 (2002) 9335-9344
59. Bartenschlager R., Frese M., and Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63 (2004) 71-180
60. Voisset C., and Dubuisson J. Functional hepatitis C virus envelope glycoproteins. Biol Cell 96 (2004) 413-420
61. Kien F., Abraham J.D., Schuster C., et al. Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins. J Gen Virol 84 Pt 3 (2003) 561-566
62. Blanchard E., Hourioux C., Brand D., et al. Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. J Virol 77 (2003) 10131-10138
63. Rodriguez-Inigo E., Bartolome J., de Lucas S., et al. Histological damage in chronic hepatitis C is not related to the extent of infection in the liver. Am J Pathol 154 (1999) 1877-1881
64. Rehermann B., and Chisari F.V. Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol 242 (2000) 299-325
65. Zhou S., Terrault N.A., Ferrell L., et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 24 (1996) 1041-1046
66. Puoti C., Stati T., and Magrini A. Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels. Liver 19 (1999) 104-109
67. Romeo R., Colombo M., Rumi M., et al. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 3 (1996) 183-190
68. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
69. Gale Jr. M., and Foy E.M. Evasion of intracellular host defense by hepatitis C virus. Nature 436 (2005) 939-945
70. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
71. Haller O., Kochs G., and Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344 (2006) 119-130
72. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 24 (2004) 439-454
73. Kawai T., and Akira S. Innate immune recognition of viral infection. Nat Immunol 7 (2006) 131-137
74. Hiscott J., Lin R., Nakhaei P., et al. MasterCARD: a priceless link to innate immunity. Trends Mol Med 12 (2006) 53-56
75. Seth R.B., Sun L., Ea C.K., et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122 (2005) 669-682
76. Diebold S.S., Kaisho T., Hemmi H., et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
77. Sen G.C., and Sarkar S.N. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev 16 (2005) 1-14
78. Yoneyama M., Kikuchi M., Natsukawa T., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5 (2004) 730-737
79. Hemmi H., Takeuchi O., Sato S., et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 199 (2004) 1641-1650
80. Sumpter Jr. R., Loo Y.M., Foy E., et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79 (2005) 2689-2699
81. Zhu H., Zhao H., Collins C.D., et al. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 37 (2003) 1180-1188
82. Li K., Foy E., Ferreon J.C., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102 (2005) 2992-2997
83. Li X.D., Sun L., Seth R.B., et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 102 (2005) 17717-17722
84. Zhu H., Zhao H., Crawford J., et al. Gene expression associated with IFN anti-hepatitis C viral activity in a replicon cell line. Hepatology 37 (2003) 1180-1188
85. Zhu H., Shang X., Terada N., et al. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem Biophys Res Commun 324 (2004) 518-528
86. Chander G., Sulkowski M.S., Jenckes M.W., et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 36 Suppl 1 (2002) S135-S144
87. Korth M.J., and Katze M.G. Evading the interferon response: hepatitis C virus and the interferon-induced protein kinase, PKR. Curr Top Microbiol Immunol 242 (2000) 197-224
88. Herion D., and Hoofnagle J.H. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 25 (1997) 769-771
89. Lin W., Choe W.H., Hiasa Y., et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 128 (2005) 1034-1041
90. Basu A., Meyer K., Ray R.B., et al. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 288 (2001) 379-390
91. Bode J.G., Ludwig S., Ehrhardt C., et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17 (2003) 488-490
92. Plumlee C.R., Lazaro C.A., Fausto N., et al. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J 2 (2005) 89
93. Lin R., Liddle C., Byth K., et al. Virus and host factors are both important determinants of response to interferon treatment among patients with chronic hepatitis C. J Viral Hepat 3 (1996) 85-96
94. Toyoda M., Kakizaki S., Horiguchi N., et al. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver 20 (2000) 305-311
95. Schiemann U., Glas J., Torok P., et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 68 (2003) 1-4
96. Namba K., Naka K., Dansako H., et al. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype. Biochem Biophys Res Commun 323 (2004) 299-309
97. Sumpter Jr. R., Wang C., Foy E., et al. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J Virol 78 (2004) 11591-11604
98. Zhu H., Nelson D.R., Crawford J.M., et al. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. J Interferon Cytokine Res 25 (2005) 528-539
99. Tagawa M., Kato N., Yokosuka O., et al. Infection of human hepatocyte cell lines with hepatitis C virus in vitro. J Gastroenterol Hepatol 10 (1995) 523-527
100. Ito T., Mukaigawa J., Zuo J., et al. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus. J Gen Virol 77 Pt 5 (1996) 1043-1054
101. Ito T., Yasui K., Mukaigawa J., et al. Acquisition of susceptibility to hepatitis C virus replication in HepG2 cells by fusion with primary human hepatocytes: establishment of a quantitative assay for hepatitis C virus infectivity in a cell culture system. Hepatology 34 (2001) 566-572
102. Kolykhalov A.A., Feinstone S.M., and Rice C.M. Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J Virol 70 (1996) 3363-3371
103. Yanagi M., Purcell R.H., Emerson S.U., et al. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 94 (1997) 8738-8743
104. Lohmann V., Korner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
105. Blight K.J., Kolykhalov A.A., and Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 290 (2000) 1972-1974
106. Blight K.J., McKeating J.A., Marcotrigiano J., et al. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77 (2003) 3181-3190
107. Zhu Q., Guo J.T., and Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 77 (2003) 9204-9210
108. Lohmann V., Hoffmann S., Herian U., et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 77 (2003) 3007-3019
109. Pietschmann T., and Bartenschlager R. The hepatitis C virus replicon system and its application to molecular studies. Curr Opin Drug Discov Devel 4 (2001) 657-664
110. Guo J.T., Zhu Q., and Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol 77 (2003) 10769-10779
111. Ikeda M., Yi M., Li K., et al. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 76 (2002) 2997-3006
112. Bartenschlager R., Kaul A., and Sparacio S. Replication of the hepatitis C virus in cell culture. Antiviral Res 60 (2003) 91-102
113. Horscroft N., Lai V.C., Cheney W., et al. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother 16 (2005) 1-12
114. Brass V., Moradpour D., and Blum H.E. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 3 (2006) 29-34
115. Heller T., Saito S., Auerbach J., et al. An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A 102 (2005) 2579-2583
116. Zhong J., Gastaminza P., Cheng G., et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102 (2005) 9294-9299
117. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
118. Lindenbach B.D., Evans M.J., Syder A.J., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
119. Kato N. Molecular virology of hepatitis C virus. Acta Med Okayama 55 (2001) 133-159
120. Kato T., Date T., Miyamoto M., et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125 (2003) 1808-1817
121. Lindenbach B.D., Meuleman P., Ploss A., et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103 (2006) 3805-3809
122. Yi M., Villanueva R.A., Thomas D.L., et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A 103 (2006) 2310-2315
123. Liu C., Zhu H., Tu Z., et al. CD8 + T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology 37 (2003) 1335-1342
124. Lanford R.E., and Bigger C. Advances in model systems for hepatitis C virus research. Virology 293 (2002) 1-9
125. Bassett S.E., Brasky K.M., and Lanford R.E. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 72 (1998) 2589-2599
126. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39 (2004) 1469-1475
127. Major M.E., Dahari H., Mihalik K., et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39 (2004) 1709-1720
128. Cooper S., Erickson A.L., Adams E.J., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 (1999) 439-449
129. Shoukry N.H., Sidney J., Sette A., et al. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol 172 (2004) 483-492
130. Farci P., Alter H.J., Govindarajan S., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 (1992) 135-140
131. Grakoui A., Shoukry N.H., Woollard D.J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
132. Xie Z.C., Riezu-Boj J.I., Lasarte J.J., et al. Transmission of hepatitis C virus infection to tree shrews. Virology 244 (1998) 513-520
133. Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 3 Suppl 2 (2005) S132-S135
134. Lemon S.M., Lerat H., Weinman S.A., et al. A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. Trans Am Clin Climatol Assoc 111 (2000) 146-156 [discussion: 156]
135. Moriya K., Fujie H., Shintani Y., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 (1998) 1065-1067
136. Chisari F.V., Pinkert C.A., Milich D.R., et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230 (1985) 1157-1160
137. Chisari F.V. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 22 4 Pt 1 (1995) 1316-1325
138. Wu G.Y., Konishi M., Walton C.M., et al. A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 128 (2005) 1416-1423
139. Guha C., Lee S.W., Chowdhury N.R., et al. Cell culture models and animal models of viral hepatitis. Part II: hepatitis C. Lab Anim (NY) 34 (2005) 39-47
140. Petersen J., Dandri M., Gupta S., et al. Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci U S A 95 (1998) 310-315
141. Galun E., Burakova T., Ketzinel M., et al. Hepatitis C virus viremia in SCID→BNX mouse chimera. J Infect Dis 172 (1995) 25-30
142. Dandri M., Burda M.R., Torok E., et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33 (2001) 981-988
143. Maeda N., Watanabe M., Okamoto S., et al. Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone. Liver Int 24 (2004) 259-267
144. Mercer D.F., Schiller D.E., Elliott J.F., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7 (2001) 927-933
145. Cagnon L., Wagaman P., Bartenschlager R., et al. Application of the trak-C HCV core assay for monitoring antiviral activity in HCV replication systems. J Virol Methods 118 (2004) 23-31
146. Meuleman P., Steyaert S., Libbrecht L., et al. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. Clin Chim Acta 366 (2006) 156-162
147. Dandri M., Burda M.R., Zuckerman D.M., et al. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes. J Hepatol 42 (2005) 54-60